ΟΣΤΕΟΠΟΡΩΣΗ ΚΑΙ ΚΑΡΚΙΝΟΣ
ΠΑΡΑΠΟΜΠΕΣ
1. Prostate cancer statistics, World Cancer Research Fund International
https://www.wcrf.org/cancer-trends/prostate-cancer-statistics/
2. Bubendorf L, Schöpfer A, Wagner U, et al. Metastatic patterns of prostate cancer: an autopsy study of 1,589 patients. Human Pathology. 2000 May;31(5):578-583. DOI: 10.1053/hp.2000.6698. PMID: 10836297.
http://europepmc.org/article/MED/10836297
3. Greenspan SL, Coates P, Sereika SM, et al. Bone loss after initiation of androgen deprivation therapy in patients with prostate cancer. The Journal of Clinical Endocrinology and Metabolism. 2005 Dec;90(12):6410-6417. DOI: 10.1210/jc.2005-0183. PMID: 16189261.
http://europepmc.org/article/MED/16189261
4. Saad F, Schulman CC. Role of bisphosphonates in prostate cancer. European Urology. 2004 Jan;45(1):26-34. DOI: 10.1016/j.eururo.2003.10.003. PMID: 14667511.
http://europepmc.org/article/MED/14667511
5. Wei JT, Gross M, Jaffe CA, et al. Androgen deprivation therapy for prostate cancer results in significant loss of bone density. Urology. 1999 Oct;54(4):607-611. DOI: 10.1016/s0090-4295(99)00301-5. PMID: 10510915.
http://europepmc.org/article/MED/10510915
6. Conde FA, Sarna L, Oka RK, et al. Age, body mass index, and serum prostate-specific antigen correlate with bone loss in men with prostate cancer not receiving androgen deprivation therapy. Urology. 2004 Aug;64(2):335-340. DOI: 10.1016/j.urology.2004.03.036. PMID: 15302490.
http://europepmc.org/article/MED/15302490
7. Smith MR, McGovern FJ, Fallon MA, et al. Low bone mineral density in hormone-naïve men with prostate carcinoma. Cancer. 2001 Jun;91(12):2238-2245. DOI: 10.1002/1097-0142(20010615)91:12<2238::aid-cncr1254>3.0.co;2-2. PMID: 11413511.
http://europepmc.org/article/MED/11413511
8. Lassemillante AC, Doi SA, Hooper JD, Prins JB, Wright OR. Prevalence of osteoporosis in prostate cancer survivors II: a meta-analysis of men not on androgen deprivation therapy. Endocrine. 2015 Nov;50(2):344-54. doi: 10.1007/s12020-015-0536-7. Epub 2015 Jan 31. PMID: 25636442.
https://pubmed.ncbi.nlm.nih.gov/25636442/
9. Diamond TH, Thornley SW, Sekel R, Smerdely P. Hip fracture in elderly men: prognostic factors and outcomes. The Medical Journal of Australia. 1997 Oct;167(8):412-415. DOI: 10.5694/j.1326-5377.1997.tb126646.x. PMID: 9364155.
http://europepmc.org/article/MED/9364155
10. Schnell S, Friedman SM, Mendelson DA, Bingham KW, Kates SL. The 1-year mortality of patients treated in a hip fracture program for elders. Geriatr Orthop Surg Rehabil. 2010 Sep;1(1):6-14. doi: 10.1177/2151458510378105. PMID: 23569656; PMCID: PMC3597289.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3597289/
11. Breast cancer, 26 March 2021, World Health Organization
https://www.who.int/news-room/fact-sheets/detail/breast-cancer
12. Chen S, Bo L, Lv D, Ma F. Bone Safety Profile of Steroidal Aromatase Inhibitor in Comparison to Nonsteroidal Aromatase Inhibitors in Postmenopausal Women with Breast Cancer: A Network Meta-Analysis. Breast Care (Basel, Switzerland). 2022 Aug;17(4):391-402. DOI: 10.1159/000523695. PMID: 36156912; PMCID: PMC9453661.
https://europepmc.org/article/MED/36156912
13.Breast cancer in women, NHS of UK
https://www.nhs.uk/conditions/breast-cancer/
14. Breast cancer in men, NHS of UK
https://www.nhs.uk/conditions/breast-cancer-in-men/
15. Bruyère O, Bergmann P, Cavalier E, Gielen E, Goemaere S, Kaufman JM, Rozenberg S, Body JJ. Skeletal health in breast cancer survivors. Maturitas. 2017 Nov;105:78-82. doi: 10.1016/j.maturitas.2017.08.008. Epub 2017 Aug 18. PMID: 28838807.
https://pubmed.ncbi.nlm.nih.gov/28838807/
16. Datta M, Schwartz GG. Calcium and vitamin D supplementation and loss of bone mineral density in women undergoing breast cancer therapy. Critical Reviews in Oncology/hematology. 2013 Dec;88(3):613-624. DOI: 10.1016/j.critrevonc.2013.07.002. PMID: 23932583; PMCID: PMC3844003.
https://europepmc.org/article/MED/23932583
17. McDonald AM, Yang ES, Saag KG, et al. Osteoporosis screening using computed tomography for men with prostate cancer: results of a prospective study. Archives of Osteoporosis. 2020 Feb;15(1):32. DOI: 10.1007/s11657-020-0711-1. PMID: 32112196; PMCID: PMC7402416.
https://europepmc.org/article/MED/32112196
18. Verwaaijen, E.J., Ma, J., de Groot-Kruseman, H.A., Pieters, R., van der Sluis, I.M., van Atteveld, J.E., Halton, J., Fernandez, C.V., Hartman, A., de Jonge, R., Lequin, M.H., te Winkel, M.L., Alos, N., Atkinson, S.A., Barr, R., Grant, R.M., Hay, J., Huber, A.M., Ho, J., Jaremko, J., Koujok, K., Lang, B., Matzinger, M.-A., Shenouda, N., Rauch, F., Rodd, C., van den Heuvel-Eibrink, M.M., Pluijm, S.M.F., Ward, L.M. and (2021), A Validated Risk Prediction Model for Bone Fragility in Children With Acute Lymphoblastic Leukemia. J Bone Miner Res, 36: 2290-2299. https://doi.org/10.1002/jbmr.4442
https://asbmr.onlinelibrary.wiley.com/doi/10.1002/jbmr.4442
1. Prostate cancer statistics, World Cancer Research Fund International
https://www.wcrf.org/cancer-trends/prostate-cancer-statistics/
2. Bubendorf L, Schöpfer A, Wagner U, et al. Metastatic patterns of prostate cancer: an autopsy study of 1,589 patients. Human Pathology. 2000 May;31(5):578-583. DOI: 10.1053/hp.2000.6698. PMID: 10836297.
http://europepmc.org/article/MED/10836297
3. Greenspan SL, Coates P, Sereika SM, et al. Bone loss after initiation of androgen deprivation therapy in patients with prostate cancer. The Journal of Clinical Endocrinology and Metabolism. 2005 Dec;90(12):6410-6417. DOI: 10.1210/jc.2005-0183. PMID: 16189261.
http://europepmc.org/article/MED/16189261
4. Saad F, Schulman CC. Role of bisphosphonates in prostate cancer. European Urology. 2004 Jan;45(1):26-34. DOI: 10.1016/j.eururo.2003.10.003. PMID: 14667511.
http://europepmc.org/article/MED/14667511
5. Wei JT, Gross M, Jaffe CA, et al. Androgen deprivation therapy for prostate cancer results in significant loss of bone density. Urology. 1999 Oct;54(4):607-611. DOI: 10.1016/s0090-4295(99)00301-5. PMID: 10510915.
http://europepmc.org/article/MED/10510915
6. Conde FA, Sarna L, Oka RK, et al. Age, body mass index, and serum prostate-specific antigen correlate with bone loss in men with prostate cancer not receiving androgen deprivation therapy. Urology. 2004 Aug;64(2):335-340. DOI: 10.1016/j.urology.2004.03.036. PMID: 15302490.
http://europepmc.org/article/MED/15302490
7. Smith MR, McGovern FJ, Fallon MA, et al. Low bone mineral density in hormone-naïve men with prostate carcinoma. Cancer. 2001 Jun;91(12):2238-2245. DOI: 10.1002/1097-0142(20010615)91:12<2238::aid-cncr1254>3.0.co;2-2. PMID: 11413511.
http://europepmc.org/article/MED/11413511
8. Lassemillante AC, Doi SA, Hooper JD, Prins JB, Wright OR. Prevalence of osteoporosis in prostate cancer survivors II: a meta-analysis of men not on androgen deprivation therapy. Endocrine. 2015 Nov;50(2):344-54. doi: 10.1007/s12020-015-0536-7. Epub 2015 Jan 31. PMID: 25636442.
https://pubmed.ncbi.nlm.nih.gov/25636442/
9. Diamond TH, Thornley SW, Sekel R, Smerdely P. Hip fracture in elderly men: prognostic factors and outcomes. The Medical Journal of Australia. 1997 Oct;167(8):412-415. DOI: 10.5694/j.1326-5377.1997.tb126646.x. PMID: 9364155.
http://europepmc.org/article/MED/9364155
10. Schnell S, Friedman SM, Mendelson DA, Bingham KW, Kates SL. The 1-year mortality of patients treated in a hip fracture program for elders. Geriatr Orthop Surg Rehabil. 2010 Sep;1(1):6-14. doi: 10.1177/2151458510378105. PMID: 23569656; PMCID: PMC3597289.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3597289/
11. Breast cancer, 26 March 2021, World Health Organization
https://www.who.int/news-room/fact-sheets/detail/breast-cancer
12. Chen S, Bo L, Lv D, Ma F. Bone Safety Profile of Steroidal Aromatase Inhibitor in Comparison to Nonsteroidal Aromatase Inhibitors in Postmenopausal Women with Breast Cancer: A Network Meta-Analysis. Breast Care (Basel, Switzerland). 2022 Aug;17(4):391-402. DOI: 10.1159/000523695. PMID: 36156912; PMCID: PMC9453661.
https://europepmc.org/article/MED/36156912
13.Breast cancer in women, NHS of UK
https://www.nhs.uk/conditions/breast-cancer/
14. Breast cancer in men, NHS of UK
https://www.nhs.uk/conditions/breast-cancer-in-men/
15. Bruyère O, Bergmann P, Cavalier E, Gielen E, Goemaere S, Kaufman JM, Rozenberg S, Body JJ. Skeletal health in breast cancer survivors. Maturitas. 2017 Nov;105:78-82. doi: 10.1016/j.maturitas.2017.08.008. Epub 2017 Aug 18. PMID: 28838807.
https://pubmed.ncbi.nlm.nih.gov/28838807/
16. Datta M, Schwartz GG. Calcium and vitamin D supplementation and loss of bone mineral density in women undergoing breast cancer therapy. Critical Reviews in Oncology/hematology. 2013 Dec;88(3):613-624. DOI: 10.1016/j.critrevonc.2013.07.002. PMID: 23932583; PMCID: PMC3844003.
https://europepmc.org/article/MED/23932583
17. McDonald AM, Yang ES, Saag KG, et al. Osteoporosis screening using computed tomography for men with prostate cancer: results of a prospective study. Archives of Osteoporosis. 2020 Feb;15(1):32. DOI: 10.1007/s11657-020-0711-1. PMID: 32112196; PMCID: PMC7402416.
https://europepmc.org/article/MED/32112196
18. Verwaaijen, E.J., Ma, J., de Groot-Kruseman, H.A., Pieters, R., van der Sluis, I.M., van Atteveld, J.E., Halton, J., Fernandez, C.V., Hartman, A., de Jonge, R., Lequin, M.H., te Winkel, M.L., Alos, N., Atkinson, S.A., Barr, R., Grant, R.M., Hay, J., Huber, A.M., Ho, J., Jaremko, J., Koujok, K., Lang, B., Matzinger, M.-A., Shenouda, N., Rauch, F., Rodd, C., van den Heuvel-Eibrink, M.M., Pluijm, S.M.F., Ward, L.M. and (2021), A Validated Risk Prediction Model for Bone Fragility in Children With Acute Lymphoblastic Leukemia. J Bone Miner Res, 36: 2290-2299. https://doi.org/10.1002/jbmr.4442
https://asbmr.onlinelibrary.wiley.com/doi/10.1002/jbmr.4442
